# Antigen expression and treatment response

Source: https://onco.cc/terms/antigen-expression-and-response/  
OnCo record `antigen-expression-and-response` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Finding a surface protein can help explain how an antibody drug reaches a tumor. The amount of protein measured in a biopsy does not describe every step needed for the treatment to work.

## Summary

Antigen measurement, drug uptake, intracellular processing and payload sensitivity describe different parts of antibody-drug conjugate activity. DAISY, a single-arm phase 2 study, examined trastuzumab deruxtecan across HER2 expression cohorts and found activity in more than one expression category. That study does not establish a universal expression cutoff or a comparative treatment effect in every cohort. A biomarker rule needs evidence for the particular drug, assay, disease and setting.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: target expression versus ADC response; antigen density and ADC response

## Sources

- DAISY: variable HER2 expression and treatment activity (2023): https://doi.org/10.1038/s41591-023-02478-2
- Cellular processing of a maytansinoid conjugate (2016): https://doi.org/10.1208/s12248-016-9892-3

## Connected records

- terms: [Antibody internalization and intracellular trafficking](https://onco.cc/terms/antibody-internalization-trafficking/), [Binding-site barrier in tumor delivery](https://onco.cc/terms/binding-site-barrier/), [Biomarker](https://onco.cc/terms/biomarker/), [Evidence from measurement to patient benefit](https://onco.cc/terms/measurement-to-benefit-evidence/), [Immunohistochemistry (IHC)](https://onco.cc/terms/ihc/), [Prognostic and predictive biomarkers](https://onco.cc/terms/prognostic-versus-predictive-biomarkers/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)

---
JSON: https://onco.cc/api/v1/entities/antigen-expression-and-response.json